The aim of our study was to describe the knowledge and practice of New Zealand anaesthetists in relation to perioperative beta-adrenergic blockade, and to define barriers to implementation of perioperative beta-blockade in surgical patients at risk of myocardial ischaemia.
Is there sufficient evidence to change practice in regard to perioperative beta-adrenergic blocker therapy? A number of randomized controlled trials have announced impressive reductions in postoperative cardiac morbidity and mortality for at-risk patients prescribed perioperative betablockers [1] [2] [3] . Two systematic reviews of the evidence have both given qualified support to perioperative use of beta-blockers 4, 5 . The American College of Physicians recommended the perioperative use of beta-blockers in 1997 6 and the most recent American Heart Association (AHA) guideline update for perioperative cardiovascular evaluation of noncardiac surgery, recommends that when possible, betablockers should be started days or weeks before elective surgery, with the dose titrated to achieve a resting heart rate of between 50 and 60 beats per minute 7 . The AHA consider there is Class I support (conditions for which there is evidence and/or general agreement that a given procedure/therapy is useful and effective) for perioperative beta-blockade in patients in whom a beta-blocker has been required to control symptoms of angina, patients with symptomatic arrhythmias or hypertension, patients with evidence of ischaemia on preoperative testing and patients undergoing vascular surgery. The AHA gives a Class IIa support (weight of evidence/opinion is in favour of usefulness/ efficacy) for instituting perioperative beta-blockade in patients in whom preoperative assessment identifies untreated hypertension, known coronary heart disease or major risk factors for coronary disease. The AHA update offers no specific guideline on treatment duration. A cautionary note has recently been raised by the PeriOperative ISchemic Evaluation (POISE) study group, who consider the evidence for perioperative beta-blockers suggestive but not definitive. The group suggests that physicians should either await the results of its trial or "use a beta-blocker in selected patients, accepting the limitations of current data" 8 .
How are these trials, reviews and guidelines affecting practice? In a recent survey of continuing education trends of New Zealand anaesthetists 9 , perioperative beta-blockade emerged as one area where anaesthetists had changed their practice. It could be assumed that anaesthetists are aware of the evidence and treat patients accordingly.
Surveys of practice in Canada, the U.S.A. and the U.K. have shown a high level of awareness of the benefit of beta-blockade, but a considerable gap between recommended management and actual practice. Few departments have protocols, and practice varies widely [10] [11] [12] . Supporting this subjective survey data, an audit of patient notes between 1997 and 2001 13 found beta-blockers were not used in the majority of patients who should benefit from them, based on Mangano's criteria 2 . These are coronary artery disease (previous myocardial infarction, typical angina, or atypical angina with a positive stress test) or two or more risk factors for coronary artery disease (age >65 years, hypertension, current smoking, raised serum cholesterol, and diabetes mellitus). There may well be regional or national variation to practice. Only one study looks at practice in Australia or New Zealand. A survey of Australian and New Zealand teaching hospital departments found that departmental attitudes to beta-blockers varied widely among the 67 responding hospitals, and only 10% had protocols 14 . There were limitations to this study. In particular, the survey was completed by a single anaesthetist for each department. This assumed an accurate knowledge on that anaesthetist's part of colleagues' behaviour. However, the author's findings were consistent with those of studies in other countries, and they suggested a need to identify the underlying reasons for this variable practice.
The aim of our study was to examine the knowledge and practice of individual New Zealand anaesthetists and to identify the underlying barriers to implementation of best practice in the use of perioperative beta-blockade.
MATERIALS AND METHODS
Ethical approval was obtained from the Wellington Hospital Ethics Committee.
A survey form was developed to seek anaesthetists' views on the perceived benefit of perioperative betablockers, understanding of a range of potential indications and contraindications, different treatment schedules used, and the availability of department protocols relating to beta-blocker use. The questionnaire sampled from the range of options and was not intended to be an exhaustive list of all possible options. In addition, anaesthetists were asked to identify barriers to implementing perioperative betablockade.
An initial pilot trialed the form on ten anaesthetists. Following modifications, the survey was sent out to all 400 specialist anaesthetists in New Zealand who had been admitted to Fellowship prior to 2003. This was based on the mailing list of the Continuing Education Committee for Anaesthesia in New Zealand. A replypaid envelope was included, which was coded to facilitate a second mail-out. The completed surveys were separated from the envelopes on opening, to maintain confidentiality of respondents. Four weeks later, non-responders were sent a second survey.
Descriptive statistics were used for categorical data. Written responses were coded and grouped into themes.
RESULTS
A total of 252 of the 400 questionnaires were returned. Eighteen of these were excluded as the respondents had either retired, or worked exclusively in paediatric anaesthesia, thus sample size was taken as 382 (down from 400). The total number of analysable questionnaires returned was 226 (eight of the returned questionnaires were blank), giving a response rate of 59% (226/382). Not all respondents completed all questions.
Ninety-five per cent of respondents were either convinced or somewhat convinced of the value of perioperative beta-blockade (221 responses to this question). Forty-five per cent of the responding anaesthetists would always or usually commence beta-blockers in patients with risk factors, and 72% would always or usually continue beta-blockers into the postoperative period once started ( Table 1) . Initiation of therapy ranged from pre-assessment clinic to theatre. It appeared more anaesthetists initiated therapy on the day of surgery, rather than in the pre-assessment clinic, but many anaesthetists did not answer all three parts of this question ( Table 2) .
Of those 203 anaesthetists responding to the question, 71% indicated that they would always or usually continue beta-blockade into the postoperative period. Duration of treatment varied from a preoperative dose only to duration of hospital stay or longer ( Table 3 ). Other options chosen in response to this question included one month post operation, as directed by the cardiologist, or as considered appropriate by the patient's general practitioner.
Factors considered indications for use of perioperative beta-blockers varied widely (Table 4) . A strong history of cardiac ischaemia was nominated by most. Risk factors for cardiac disease such as diabetes, hypercholesterolaemia, and diabetes were infrequently chosen, as was a history of congestive cardiac failure. Thirty-two per cent of responding anaesthetists did not consider current treatment with beta-blockers as an indication for perioperative beta-blockade (Table 4 ). Factors nominated as contraindications for perioperative beta-blockade also varied ( Table 5) .
When prescribing a beta-blocker for prophylaxis against myocardial ischaemia, preferences were for atenolol (n=111) and metoprolol (n=146), over esmolol (n=46) or propanolol (n=3).
Sixty-five per cent of 204 respondents aimed for a target heart rate. Of these, 72% aimed for rates of 70 or less, while the remainder tolerated rates above 70 beats per minute (Table 6 ). Written department protocols for perioperative beta-blockade were available to 20% of the 207 respondents, while 62% did not have a protocol and 9% did not know. The remaining 9% of anaesthetists replied that they worked exclusively in private practice.
At least one impediment to beta-blocker therapy was identified by 181 of the 226 respondents (80%). Seventeen per cent chose uncertainty around indications, choice of drug, dose or timing of therapy as impediments to beta-blockade ( Table 7) . did not know or felt their practice probably was not based on best evidence.
DISCUSSION
This survey on use of perioperative beta-blockers reveals a gap between current practice guidelines and the self-reported clinical practice of anaesthetists in New Zealand. The reasons for this gap between guidelines and practice appear to be multi-factorial. Although most anaesthetists were convinced of the potential benefits of perioperative beta-blockade, many were not confident they followed best practice, and responses showed a lack of consensus on prescribing patterns, indications and contraindications. For example, a significant number of anaesthetists considered peripheral vascular disease and diabetes contraindications, whereas the evidence would suggest these patients would have most to gain from perioperative beta-blockade. There were logistic difficulties instituting and monitoring treatment, particularly where this required collaboration across professional boundaries. Few departments had written protocols. In addition, many were concerned about risks of beta-blockers in combination with other therapies in particular, epidural analgesia.
Variation in clinical practice has been identified as an important problem 15 in healthcare. This study shows that the problem extends to anaesthesia.
Our study is consistent with the results of other studies in this area and broadens this body of work by identifying barriers to implementation of practice guidelines in New Zealand. Identification of these barriers is the first step in overcoming them.
Recognized weaknesses of surveys include the representativeness of responders and the accuracy of self-reporting. The response rate of 59% is consistent with rates from similar surveys, but clearly there may be a responder bias. Nevertheless, our results describe the practice of around half of New Zealand specialist anaesthetists. As the survey questions were limited in scope and did not include all possible options, the results do not represent a thorough and reliable assessment of New Zealand anaesthetists' knowledge, but rather an indication of variation in practice. Self-reporting can be inaccurate. Audit of charts may be a more accurate method of documenting practice, as in the study by Siddiqui 13 , but one of the strengths of our study was to explore the underlying reasons for failure to prescribe beta-blockers in the perioperative period, which would not be revealed in chart reviews.
Implementing practice guidelines is known to be difficult. It cannot be assumed that publication of guidelines, attendance at conferences and publication (15) In addition, 55 anaesthetists gave written responses related to barriers to implementation of perioperative beta-blockade. A number of themes emerged. Logistical themes included the inability of patients to take oral medications, the need to educate colleagues of the benefit of treatment, problems with ensuring treatment continued in the postoperative period and difficulties of instituting therapy preoperatively. The need for follow-up and monitoring with dose adjustment made some reluctant to initiate such therapy.
Some anaesthetists felt that the responsibility for instituting beta-blocker therapy lay with other groups (GPs or cardiologists), who were in a position to care for the patient long-term, and take overall care of the patient. The lack of clear guidelines and department protocols and a desire for more convincing evidence on benefit, timing, dosage and indications of beta-blockers also prevented some from initiating this therapy. Concerns about risks of beta-blocker therapy included hypotension if combined with general or regional anaesthesia, or if added to other antihypertensive medication. In particular, anaesthetists working in intensive care units were concerned that beta-blockers combined with epidural analgesia might result in hypotension and bradycardia requiring inotropic support.
Only 14% of 202 respondents felt confident that their practice was based on best available evidence, while 44% felt it probably was. The remaining 42% of original research and systematic reviews will lead to change in practice 16 . Based on systematic reviews of the literature, Davis et al 17, 18 suggested that there are serious deficiencies in the translation of best evidence to practice. This problem has been demonstrated previously with the introduction of thrombolysis for acute myocardial infarction 19 , where it was many years from the time of publication of convincing evidence to the time of widespread implementation. More recently, an audit of practice indicated major deficiencies in delivery of well researched secondary prevention measures for stroke victims 20 .
A new guideline needs to be convincing to change practice 18 . Part of the problem in the case of betablockers is that the evidence required to direct clear and comprehensive guidelines is incomplete, and there is some question over the magnitude of the benefit. The POISE trial 8 may provide some of the answers to the extent of the benefit, but questions remain regarding patient selection and treatment schedules. There has been an assumption by many investigators that the indications for perioperative beta-blockade are the same as the risk factors for perioperative myocardial ischaemia, but this may not necessarily be the case. Likewise, treatment schedules for perioperative beta-blockade have been based on management of cardiac ischaemia in the non-surgical patient. Impact on specific groups of patients such as those on other antihypertensive agents, those receiving epidural analgesia, or those at risk of hypovolaemia has not been investigated, and is not addressed in the AHA guidelines. As such, the current guidelines are not well specified and do not meet the requirement identified by Davis et al of a high quality guideline 18 .
In addition, there are practical difficulties in administration of beta-blockers in the pre-and postoperative period which create an impediment for many anaesthetists. Davis et al found that the ease with which the new practice could be implemented was an important component in the success of a guideline 18. Clearly, perioperative beta-blockade therapy is not easy to implement and involves multiple professional groups who all need to be committed to the change.
In order to change physician practice, there must be convincing evidence for the need to change, a clear protocol for the new treatment, consensus among colleagues and between professional groups, and organizational support for change. A variety of interventions are required, and these must target groups at all levels involved with patient care 18, [21] [22] [23] . Of interest, a recent study 24 reported successful implementation of a perioperative beta-blocker protocol in one hospital. The strategy involved 'close collaboration between anaesthetists, internists, PACU nurses and family physicians'. Studies such as this, demonstrating effective implementation strategies, will be influential in more widespread adoption of best practice. However, even with such careful planning, the protocols in the study were not followed in the immediate post-anaesthesia period in over 10% of patients.
This study has identified variations in practice and the reasons why New Zealand anaesthetists may be reluctant to implement perioperative beta-blockade. Deficiencies in the guidelines are part of the problem. However, even with consensus on guidelines, effective multidisciplinary strategies will be required to change practice.
